(Q46964646)

26 December 2017

title

Atenolol and cardiovascular risk: an issue close to the heart (English)

1 reference

26 December 2017

author name string

Ian B Wilkinson

series ordinal

1

1 reference

26 December 2017

Carmel M McEniery

series ordinal

2

1 reference

26 December 2017

John R Cockcroft

series ordinal

3

1 reference

26 December 2017

language of work or name

English

0 references

publication date

1 February 2006

1 reference

26 December 2017

published in

The Lancet

1 reference

26 December 2017

volume

367

1 reference

26 December 2017

issue

9511

1 reference

26 December 2017

page(s)

627-629

1 reference

26 December 2017

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968238-X

7 January 2021

Cardiovascular protection and blood pressure reduction: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968238-X

7 January 2021

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968238-X

7 January 2021

Atenolol in hypertension: is it a wise choice?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968238-X

7 January 2021

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968238-X

7 January 2021

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968238-X

7 January 2021

Formation of peripheral pulse contour in man

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968238-X

7 January 2021

Central pulse pressure and mortality in end-stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968238-X

7 January 2021

Effect of different antihypertensive drug classes on central aortic pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968238-X

7 January 2021

Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968238-X

7 January 2021

Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968238-X

7 January 2021

The influence of heart rate on augmentation index and central arterial pressure in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968238-X

7 January 2021

Arterial dilation and reduced wave reflection. Benefit of dilevalol in hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968238-X

7 January 2021

Pulse wave analysis and hypertension: evangelism versus scepticism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968238-X

7 January 2021

Cholesterol, endothelial function and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968238-X

7 January 2021

10.1016/S0140-6736(06)68238-X

Identifiers

DOI

1 reference

26 December 2017

PubMed ID

16503444

1 reference

26 December 2017